STTR Phase I: Formulation of a COVID-19 mRNA Vaccine by Inverse Flash NanoPrecipitation — NSF Award to Optimeos Life Sciences, Inc
The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is the development of a novel messenger ribonucleic acid (mRNA)-based vaccine for COVID-19. The fastest-to-clinic vaccine for COVID-19 was mRNA-based; however, there are no mRNA-based vaccines on the market cu
| Award title | STTR Phase I: Formulation of a COVID-19 mRNA Vaccine by Inverse Flash NanoPrecipitation |
|---|---|
| Award ID | 2032023 |
| Awardee | Optimeos Life Sciences, Inc. |
| City | PRINCETON |
| State | NJ |
| Amount obligated | $256,000 |
| Principal investigator | Robert Pagels |
| Program | STTR Phase I |
| Start date | 12/15/2020 |
| Abstract | The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is the development of a novel messenger ribonucleic acid (mRNA)-based vaccine for COVID-19. The fastest-to-clinic vaccine for COVID-19 was mRNA-based; however, there are no mRNA-based vaccines on the market currently. This is, in part, because this class of vaccines is difficult to optimize and manufacture at a large scale. If clinical trials are successful, hundreds of millions of dose |
| Source | NSF Awards |
$799/mo
Try NSFGrants →